Showing results (111-120 of 394) with videos related to
Sort By:
Pageof 40
British Journal of Haematology|July 9, 2003
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myelomaPeter Liebisch, Andreas Viardot, Nicole Bassermann, et al.Neoplasia (New York, N.Y.)|December 14, 2020
U-RT1 - A new model for Richter transformationTeresa Schmid, Julia Maier, Melanie Martin, et al.Proceedings of the National Academy of Sciences of the United States of America|May 11, 2006
Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanismDaniel Mertens, Stephan Wolf, Cordula Tschuch, et al.Blood|October 11, 2014
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Peter Dreger, Johannes Schetelig, Niels Andersen, et al.International Journal of Cancer|May 16, 2014
Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6Nupur Bhattacharya, Michaela Reichenzeller, Maiwen Caudron-Herger, et al.Frontiers in Oncology|March 8, 2021
Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-AnalysisKonstantinos Christofyllakis, Claudia Pföhler, Moritz Bewarder, et al.British Journal of Haematology|May 28, 2011
Nurse-like cells show deregulated expression of genes involved in immunocompetenceNupur Bhattacharya, Susanne Diener, Irina S Idler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genesDirk L Kienle, Christian Korz, Beate Hosch, et al.British Journal of Haematology|January 16, 2007
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapseMark Ringhoffer, Stephanie von Harsdorf, Michael Schmitt, et al.Future Oncology (London, England)|July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progressionPetra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.Pageof 40